<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00596297</url>
  </required_header>
  <id_info>
    <org_study_id>IBEVI</org_study_id>
    <secondary_id>7309/2007</secondary_id>
    <nct_id>NCT00596297</nct_id>
  </id_info>
  <brief_title>Preoperative Bevacizumab for Vitreous Hemorrhage</brief_title>
  <acronym>IBEVI</acronym>
  <official_title>Intra-Operative and Postoperative Intraocular Bleeding After Pars Plana Vitrectomy for Vitreous Hemorrhage in Diabetic Patients Previously Treated With Intravitreal Bevacizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether preoperative intravitreal bevacizumab is
      effective in reducing intra-operative and postoperative bleeding in diabetic patients
      submitted to pars plana vitrectomy for vitreous hemorrhage.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intra- and postoperative intra-ocular bleeding</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <condition>Vitreous Hemorrhage</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative Intravitreal bevacizumab and pars plana vitrectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pars plana vitrectomy only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Intravitreal bevacizumab (1.5 mg; 0,06 ml) 1 day after baseline; pars plana vitrectomy 4 weeks after baseline</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pars plana vitrectomy</intervention_name>
    <description>4 weeks after baseline</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetic retinopathy causing significant vitreous hemorrhage with visual acuity loss
             lasting more than three months in patients not previously treated and four months in
             those previously LASER treated.

        Exclusion Criteria:

          -  Previous intra-ocular surgery other than cataract surgery

          -  Retinal detachment

          -  Use of anticoagulants drugs other than aspirin

          -  Vitreous hemorrhage clearance at week-3 study period

          -  History of previous thromboembolic events
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel R Lucena, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinics Hospital of Ribeirão Preto, School of Medicine of Ribeirão Preto, USP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinics Hospital of Ribeirão Preto, School of Medicine of Ribeirão Preto, USP</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>São Paulo</state>
        <zip>14049-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2008</study_first_submitted>
  <study_first_submitted_qc>January 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2008</study_first_posted>
  <last_update_submitted>October 2, 2008</last_update_submitted>
  <last_update_submitted_qc>October 2, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2008</last_update_posted>
  <responsible_party>
    <name_title>Daniel da Rocha Lucena</name_title>
    <organization>Clinics Hospital of Ribeirão Preto, School of Medicine of Riberião Preto, University of São Paulo</organization>
  </responsible_party>
  <keyword>Diabetic Retinopathy</keyword>
  <keyword>Vitreous Hemorrhage</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>pars plana vitrectomy</keyword>
  <keyword>preoperative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Vitreous Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Temazepam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

